

**Question for written answer E-000811/2022
to the Commission**

Rule 138

Christine Anderson (ID)

Subject: Powerful warning in connection with the reporting of COVID-19 vaccination side-effects and the importance attached to the vaccination strategy relative to support for therapeutics

A German health insurance fund has contacted the Paul Ehrlich Institute after data suggested that there is very significant under-reporting of suspected cases of COVID-19 vaccination side-effects¹. The health insurance fund suspects that, in many instances, physicians fail to notify vaccine adverse events because no payment is made for reporting vaccine side-effects and the reporting process is very involved. Physicians have told the health insurance fund that reporting a suspected vaccine adverse event takes about half an hour. It can therefore be assumed that there are probably about three million suspected cases of vaccine side-effects.

In addition, the Commission has launched an EU Strategy on COVID-19 Therapeutics² and, to date, has authorised seven COVID-19 therapeutics and concluded three joint procurement contracts for the purchase of COVID-19 therapeutics. Support amounts to EUR 5 million (EU4Health), EUR 90 million (emergency work programme for health and infrastructures) and also covers research projects with a total value of EUR 119 million³.

In terms of scale, this is in no way comparable with the billions in orders that the Commission is investing in its vaccination strategy.

1. With regard to the authorisation of vaccines and subsequent vaccination strategy, how does the Commission view the feedback from the health insurance fund referred to?
2. Why is the Commission disadvantaging research into effective therapeutics over vaccines, especially in the light of the numerous cases of vaccine failure?

¹ <https://bkk-provita.de/wp-content/uploads/2022/02/Paul-Ehrlich-Institut-Pressinformation-Impfnebenwirkungen-nach-Corona-Impfung-1.pdf>

² https://ec.europa.eu/info/sites/default/files/communication-strategy-covid-19-therapeutics_en.pdf

³ https://ec.europa.eu/info/sites/default/files/communication-strategy-covid-19-therapeutics_en.pdf